TrialPloS one2016

An Open-Label Trial of 12-Week Simeprevir plus Peginterferon/Ribavirin (PR) in Treatment-Naïve Patients with Hepatitis C Virus (HCV) Genotype 1 (GT1).

Tarik Asselah et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.